Skip to content

Journal · Breast cancer · Updated 22 November 2026

Current Breast Cancer Reports

Read Current Breast Cancer Reports articles on DeepDyve. No university library needed.

Current Breast Cancer Reports has published since 2009 and runs reviews on breast cancer research and care, with recent papers on skipping axillary surgery, “chemo brain” in survivors, risk calculators, metastatic triple-negative disease and active monitoring of DCIS. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Current Breast Cancer Reports
Journal cover

Current Breast Cancer Reports at a glance

Full title
Current Breast Cancer Reports
Abbreviation (NLM)
Curr Breast Cancer Rep
Publisher
Springer Nature
Print ISSN
1943-4588
Online ISSN (eISSN)
1943-4596
First published
2009
Access model
Hybrid (49% free to read in 2026)

Ways to access Current Breast Cancer Reports

49% of the articles Current Breast Cancer Reports published from January 1 to November 20, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 49% of Current Breast Cancer Reports articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Current Breast Cancer Reports. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Current Breast Cancer Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Current Breast Cancer Reports’ 2025 Journal Impact Factor is 1.0, and its 5-year Impact Factor is 1.2.

1.0

Journal Impact Factor (2025)

1.2

5-year Impact Factor (2025)

3 days

Median time to first decision

Source: journal metrics on the Current Breast Cancer Reports homepage (Springer Nature), checked November 22, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Current Breast Cancer Reports research worth reading

Published January to October 2026. Summaries describe what the authors report.

  1. Open accessBreast surgery · Treatment planning

    Omission of Axillary Surgery in Early-Stage Breast Cancer: Implications for Multidisciplinary Decision-Making

    The authors review how the SOUND and INSEMA trials, which showed sentinel lymph node biopsy can be safely omitted in selected early-stage patients, are reshaping decisions on systemic therapy, radiation field design and trial eligibility without nodal data.

    Grasso et al. · Current Breast Cancer Reports, published online February 20, 2026 · DOI 10.1007/s12609-026-00637-1

  2. LitStreamSurvivorship · Cognitive impairment

    Neurocognitive Dysfunction (‘Chemo Brain’) in Breast Cancer Survivors: Mechanisms and Emerging Therapeutic Strategies

    The authors review chemotherapy-related cognitive impairment in breast cancer survivors, reported in about 30–40% of patients, covering mechanisms such as neuroinflammation and oxidative stress, the lack of approved drugs, and emerging neuroprotective, nanotechnology and digital approaches.

    Shadab et al. · Current Breast Cancer Reports, published online May 21, 2026 · DOI 10.1007/s12609-026-00655-z

  3. LitStreamRisk prediction · Health equity

    Inequities in Breast Cancer Risk Calculators

    The authors review breast cancer risk models and report that the Gail, Tyrer-Cuzick and BCSC models perform best in White women, the updated BCSC shows the most promise across groups, and the BWHS calculator is most accurate for Black women.

    Rangel et al. · Current Breast Cancer Reports, published online January 12, 2026 · DOI 10.1007/s12609-025-00632-y

  4. LitStreamTriple-negative breast cancer · Targeted therapy

    Evolving Frontiers in Metastatic Triple-Negative Breast Cancer: Therapeutic Strategies and Emerging Paradigms

    The authors review the shift in metastatic triple-negative breast cancer from chemotherapy toward biomarker-informed treatment, including trials supporting trop-2 antibody–drug conjugates as frontline therapy, and discuss drug sequencing, predictive biomarkers and therapeutic resistance.

    Pereira et al. · Current Breast Cancer Reports, published online June 23, 2026 · DOI 10.1007/s12609-026-00647-z

  5. LitStreamDCIS · Active monitoring

    Active Monitoring for Low-Risk Ductal Carcinoma In Situ after COMET: Evidence Boundaries, Patient Selection, and Diagnostic Reassessment

    The authors review active monitoring of low-risk ductal carcinoma in situ after the COMET trial, arguing it offers short-term randomized support for a preference-sensitive option in selected patients while complete excision remains the guideline-supported standard.

    Jiang et al. · Current Breast Cancer Reports, published online October 27, 2026 · DOI 10.1007/s12609-026-00679-5

See every Current Breast Cancer Reports article on DeepDyve

Questions about Current Breast Cancer Reports

How can I read Current Breast Cancer Reports articles without a subscription?

49% of Current Breast Cancer Reports articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Breast Cancer Reports articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Current Breast Cancer Reports?

Current Breast Cancer Reports’ NLM (PubMed) abbreviation is Curr Breast Cancer Rep.

What is the ISSN of Current Breast Cancer Reports?

The print ISSN is 1943-4588 and the online ISSN is 1943-4596.

What is the impact factor of Current Breast Cancer Reports?

Current Breast Cancer Reports’ Journal Impact Factor is 1.0 (2025), and its 5-year Impact Factor is 1.2, according to Springer Nature’s published metrics.

Is Current Breast Cancer Reports open access?

Current Breast Cancer Reports is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 20, 2026, 28 of 57 Current Breast Cancer Reports articles (49%) carry a Creative Commons license, per Crossref.

Current Breast Cancer Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 22 November 2026.

Start reading Current Breast Cancer Reports today

One month free, then less than $2 a day. Current Breast Cancer Reports, plus millions of articles from thousands of journals.

Start free month

Like this: